Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
What happened
FDA reviewed the Clover Meds website (clovermeds.com) in March 2026 and found it offers compounded semaglutide and tirzepatide drug products. The pictured product labels name "Clover Meds," which suggests the company compounds the drugs when it does not. The site also says the products come from "FDA-licensed Facilities," a designation FDA does not give to compounding pharmacies or outsourcing facilities.
What FDA found
The product labels shown on the website carry the Clover Meds name, implying the company made the drugs when it did not.
FD&C Act section 502(a) [21 U.S.C. 352(a)]; 21 C.F.R. 201.1(h)(2)The website says the products are sourced from "FDA-licensed Facilities," but FDA does not approve or license compounding pharmacies or outsourcing facilities.
FD&C Act sections 502(a) and 502(bb) [21 U.S.C. 352(a) and 352(bb)]Because of these claims, the drugs are misbranded and were offered for introduction into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. 331(a)]The compounded semaglutide and tirzepatide are "new drugs" that are not generally recognized as safe and effective, so they must meet the conditions of sections 503A or 503B to be exempt from new drug approval requirements.
FD&C Act sections 503A and 503B [21 U.S.C. 353a and 353b]
What FDA wants
FDA tells the company to send a written response to its Office of Compounding Quality and Compliance within 15 business days, describing the steps taken to fix the violations and prevent them from recurring. The response should identify who makes the compounded products, include sample labeling, and show that misleading website claims were corrected or removed.
Who should pay attention
- telehealth platforms selling compounded semaglutide or tirzepatide
- compounding pharmacies and outsourcing facilities whose products are resold by others
- marketing and regulatory teams that write website claims about FDA status
This is a summary. Read the original letter on fda.gov.